Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Other Accumulated Expenses (2020 - 2026)

Immunome filings provide 5 years of Other Accumulated Expenses readings, the most recent being $3.2 million for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 162.4% to $3.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.2 million, a 162.4% increase, with the full-year FY2025 number at $3.6 million, down 54.55% from a year prior.
  • Other Accumulated Expenses hit $3.2 million in Q1 2026 for Immunome, down from $3.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $8.0 million in Q4 2024 to a low of $229000.0 in Q4 2022.
  • Median Other Accumulated Expenses over the past 5 years was $1.2 million (2025), compared with a mean of $2.2 million.
  • Biggest five-year swings in Other Accumulated Expenses: soared 2630.93% in 2024 and later tumbled 81.23% in 2025.
  • Immunome's Other Accumulated Expenses stood at $229000.0 in 2022, then skyrocketed by 219.65% to $732000.0 in 2023, then soared by 989.89% to $8.0 million in 2024, then plummeted by 54.55% to $3.6 million in 2025, then fell by 12.44% to $3.2 million in 2026.
  • The last three reported values for Other Accumulated Expenses were $3.2 million (Q1 2026), $3.6 million (Q4 2025), and $1.7 million (Q3 2025) per Business Quant data.